Search results
Oxford Nanopore Technologies Eyes TB Test as First In-House-Developed Diagnostic Test
GenomeWeb News· 8 hours agoOxford Nanopore Technologies has been working on a tuberculosis drug resistance sequencing assay that it hopes will become its first in vitro diagnostic ...
Antibiotic resistance causing large avoidable death toll, doctors say
dpa international via Yahoo News· 3 hours agoAround 750,000 of the almost 5 million annual deaths caused by antimicrobial resistance - when...
Over 750,000 antimicrobial resistance deaths preventable yearly via vaccines, water, sanitation and...
Medical Xpress· 5 hours agoAuthors say if the world does not prioritize action on AMR now, we will see a steady increase in the...
Delhi HC closes PIL on medicine shortage in Rajan Babu Institute after govt's assurance
Investing.com· 22 hours agoThe decision came after a division bench of Acting Chief Justice Manmohan and Justice Manmeet PS...
How biologics can help with symptoms of Crohn's
Medical News Today· 6 days agoBiologic therapies for Crohn’s disease (CD) do more than reduce the common symptoms of diarrhea, abdominal cramping, and pain. CD and ulcerative colitis...
Celltrion USA announces two-year data for ZYMFENTRA™(infliximab-dyyb) to be presented at Digestive...
The Pendulum· 7 days agoCelltrion USA today announced it will present the two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) in adult patients with moderately to severely active Crohn's ...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Morningstar· 3 days agoTeva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO),today announced the availability of SIMLANDI (adalimumab-ryvk) ...
MedPod Today: RFK Jr.'s Ailments; Tenpenny Gets License Back; Shady Stem Cell Shots
MedPage Today· 7 days agoThen Kristina Fiore tells us about how the doctor who said that the COVID vaccine can magnetize...
More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved...
WTRF Wheeling· 3 days agoIn Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's disease, with or without previous biologic failure, achieved statistically ...
UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in...
KTLA-TV Los Angeles· 16 hours agoUCB, a global biopharmaceutical company, today announced that The Lancet has published results from the Phase 3 BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of BIMZELX ...